The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer

• Published in: BMC cancer Vol. 23; no. 1; pp. 1 - 7
• Main Authors: Chen, Jian-Xin, Huang, Wen-Ting, Zhang, Qing-Yun, Deng, Cheng-En, Wei, Jue-ling, Xie, Yuan-Liang, Lin, Rui, Feng, Guan-Zheng, Yang, Guang-Lin, Long, Jun, Lu, Hao-Yuan, Mo, Zeng-nan
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 23.10.2023; BioMed Central; BMC
• Subjects: BCG; BCG vaccines; Bladder cancer; Cancer; Care and treatment; Chemotherapy; Cohort analysis; Diagnosis; Dosage and administration; Drug dosages; Immunotherapy; Intravesical chemotherapy; Invasiveness; Medical research; Medical treatment; Medicine, Experimental; Non-muscle-invasive Bladder cancer; Patient outcomes; Patients; Pirrubicin; Relapse; Risk factors; Survival; Tumor recurrence; Tumors; Urology; China; Taiwan

Objective Although the current European Association of Urology(EAU) guideline recommends that patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) should accept intravesical chemotherapy or Calmette-Guerin (BCG) for no more than one year after transurethral resection of bladder...